Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3 Study to Assess the Safety and Efficacy of MultiStem® Therapy in Subjects With Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease (COVID-19)

NCT04367077 is registered in ClinicalTrials.gov with Healios K.K. as lead sponsor.

NCT NCT04367077
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04367077 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3 Study to Assess the Safety and Efficacy of MultiStem® Therapy in Subjects With Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease (COVID-19)
Lead sponsor
Healios K.K.
Phase
Phase 2/3
Overall status
Terminated
Start date
April 28, 2020
Completion date
October 1, 2024
Enrollment
206 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

ards